Opendata, web and dolomites

JEM Phase 1

JEM: The world safest subcutaneous, enclosed, biocompatible implantable device, attached directly to a AV fistula or graft or vein, for chronic disease patients in need of repetitive vascular access

Total Cost €


EC-Contrib. €






 JEM Phase 1 project word cloud

Explore the words cloud of the JEM Phase 1 project. It provides you a very rough idea of what is the project "JEM Phase 1" about.

repair    solutions    life    gold    fistula    savings    improves    chemotherapy    patient    position    victims    multiplied    medications    8k    buttonhole    markets       digestive    dialysis    enclosed    patients    market    first    estimate    pediatric    regular    reducing    easier    techniques    perforation    mortality    200m    transfusions    sold    disorders    hemolysis    usually    gauge    offers    potentially    lowering    conservative    healthcare    medical    pain    needle    undergo    clinicians    patented    eliminates    clinical    spot    prevents    universal    puncturing    specially    wall    oncology    subcutaneous    attached    implantable    hematomas    back    trained    times    player    larger    provides    flow    company    continually    accurate    reduces    risk    lifespan    standard    hemodialysis    seek    repetitive    jem    graft    morbidity    blood    vascular    device    thereby    designed    longevity    burn    requiring    vein    replacement    made    home    safer    operations    technique    causing    save    period    advantages    blunt    receiving   

Project "JEM Phase 1" data sheet

The following table provides information about the project.


Organization address
address: 11 HAGRA STREET
postcode: 4252008
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACCESS FOR LIFE IL (NETANYA) coordinator 50˙000.00


 Project objective

'JThe JEM project aims to bring to the healthcare and medical device markets the first subcutaneous enclosed implantable device attached directly to a vein, fistula or graft. The JEM is based on a patented design that greatly improves repetitive vascular access techniques and provides safer, more accurate and effective results. The JEM provides the following advantages: • It is based on the European Gold Standard 'buttonhole technique' for vascular access. • It greatly reduces costs by reducing the need for fistula repair & replacement. • It enables repetitive puncturing at the same spot by less-trained clinicians. • Its 6-year lifespan, 3 times the average fistula lifespan, reduces mortality & morbidity. • Its specially designed needle prevents back wall perforation and hematomas. • It will allow for a larger gauge needle thereby potentially increasing blood flow and lowering the risk of hemolysis. • It can be made to use a unique blunt needle that is sold by Access for Life, causing less pain to the patients ensuring easier and safer home hemodialysis. JEM devices from Access for Life are designed for all patients in need of repetitive vascular access: hemodialysis patients, oncology patients receiving chemotherapy, patients with blood disorders, patients requiring regular medications or blood transfusions, burn victims, pediatric patients and patients with digestive disorders. Due to its longevity, JEM eliminates three of the four operations dialysis patients usually undergo in a 6-year period. This will save healthcare systems about 5,8K € per dialysis patient. Multiplied by the growing number of patients, a conservative estimate of potential savings is over 200M € a year. Through the JEM project, we seek to position our company as the leading player in medical devices for repetitive vascular access, a market that is continually growing. Access for Life offers universal solutions for a wide range of clinical applications that require vascular access.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "JEM PHASE 1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "JEM PHASE 1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More